Log in

3378 Hanx Biopharmaceuticals (Wuhan) Co. Ltd. HKEX · China

Hanx Biopharmaceuticals (Wuhan) Co. (3378) news

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 3378, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Hanx Biopharmaceuticals (Wuhan) Co. news

We have not published a story on Hanx Biopharmaceuticals (Wuhan) Co. yet. When there is news, it will appear here.

Questions about Hanx Biopharmaceuticals (Wuhan) Co.

What is the ticker symbol of Hanx Biopharmaceuticals (Wuhan) Co.?

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. trades under the ticker 3378 on HKEX.

Where is Hanx Biopharmaceuticals (Wuhan) Co. listed?

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. is listed on HKEX.

Which country or territory is Hanx Biopharmaceuticals (Wuhan) Co. listed under?

Our directory records Hanx Biopharmaceuticals (Wuhan) Co. Ltd. under China.

What does Hanx Biopharmaceuticals (Wuhan) Co. do?

Our directory classifies Hanx Biopharmaceuticals (Wuhan) Co. Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Hanx Biopharmaceuticals (Wuhan) Co.?

The ISIN recorded for Hanx Biopharmaceuticals (Wuhan) Co. Ltd. is CNE100007C34.

Does aibio.space cover Hanx Biopharmaceuticals (Wuhan) Co.?

aibio.space lists Hanx Biopharmaceuticals (Wuhan) Co. Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Hanx Biopharmaceuticals (Wuhan) Co.?

Companies in our directory listed in the same country and business area as Hanx Biopharmaceuticals (Wuhan) Co.: Shanghai RAAS Blood Products Co., Wuhan Healthgen Biotechnology, Hualan Biological Engineering, Shenzhen Kangtai Biological Products Co., LongBio Pharma (Suzhou) Co., Wuxi Biologics (Cayman).

Investor discussion: Hanx Biopharmaceuticals (Wuhan) Co.

Members talk about Hanx Biopharmaceuticals (Wuhan) Co. (3378). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Hanx Biopharmaceuticals (Wuhan) Co., newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: PROPOSED PLACING OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE. Source

  2. Financings

    Share or debt issue: (1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE SUPERVISORS COMMITTEE (3) 2025 ANNUAL REPORT (4) 2025 FINAL FINANCIAL REPORT AND 2026 FINANCIAL BUDGET REPORT (5) RE-APPOINTMENT OF AUDITOR (6) 2026 DIRECTORS REMUNERATION PLAN (7) 2025 PROFIT DISTRIBUTION PLAN (8) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION (9) GENERAL MANDATE TO ISSUE ADDITIONAL H SHARES AND SALE OR TRANSFER OF TREASURY SHARES (10) GENERAL MANDATE TO REPURCHASE H SHARES AND NOTICE OF ANNUAL GENERAL MEETING. Source

  3. Financings

    Share or debt issue: PROPOSAL FOR GRANTING THE GENERAL MANDATE TO REPURCHASE H SHARES AND NOTICE OF EXTRAORDINARY GENERAL MEETING. Source

  4. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Hanx Biopharmaceuticals (Wuhan) Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT ENTERING INTO STRATEGIC COOPERATION WITH XTALPI

  2. HKEXnews

    PROPOSED PLACING OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE

  3. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT REGARDING COLLABORATION BETWEEN HANX BIOPHARMACEUTICALS AND HUST ADVANCED INTERDISCIPLINARY RESEARCH CENTRE ON AI-DRIVEN DRUG DISCOVERY

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT HANX BIOPHARMACEUTICALS AND TWINEDGE BIOSCIENCE INITIATE AI-DRIVEN DRUG DEVELOPMENT COLLABORATION

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT NOTICE ON VOLUNTARY EXTENSION OF LOCK-UP PERIOD BY SHAREHOLDERS

  7. HKEXnews

    Articles of Association

  8. HKEXnews

    ANNOUNCEMENT (1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON JUNE 24, 2026; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT INCLUSION OF HANX BIOPHARMACEUTICALS IN THE FTSE GLOBAL MICRO CAP INDEX

  10. HKEXnews

    NOTICE OF THE ANNUAL GENERAL MEETING

  11. HKEXnews

    (1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE SUPERVISORS COMMITTEE (3) 2025 ANNUAL REPORT (4) 2025 FINAL FINANCIAL REPORT AND 2026 FINANCIAL BUDGET REPORT (5) RE-APPOINTMENT OF AUDITOR (6) 2026 DIRECTORS REMUNERATION PLAN (7) 2025 PROFIT DISTRIBUTION PLAN (8) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION (9) GENERAL MANDATE TO ISSUE ADDITIONAL H SHARES AND SALE OR TRANSFER OF TREASURY SHARES (10) GENERAL MANDATE TO REPURCHASE H SHARES AND NOTICE OF ANNUAL GENERAL MEETING

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT HANX BIOPHARMACEUTICALS PRESENTED FOUR POSTER PRESENTATIONS AT THE 2026 AACR MEETING

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT HANX BIOPHARMACEUTICALS TO PRESENT FOUR POSTER PRESENTATIONS AT THE 2026 AACR MEETING

  14. HKEXnews

    PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  15. HKEXnews

    CONTINUING CONNECTED TRANSACTIONS REVISION OF ANNUAL CAPS

  16. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

  17. HKEXnews

    ANNOUNCEMENT POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 12, 2026

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT HX111 COMPLETES FIRST PATIENT DOSING

  19. HKEXnews

    (1) RE-DESIGNATION FROM NON-EXECUTIVE DIRECTOR TO EXECUTIVE DIRECTOR; (2) CHANGE IN THE COMPOSITION OF THE BOARD COMMITTEE; (3) RESIGNATION OF JOINT COMPANY SECRETARY, CHIEF FINANCIAL OFFICER, SECRETARY OF THE BOARD AND VICE GENERAL MANAGER; AND (4) APPOINTMENT OF CHIEF FINANCIAL OFFICER AND SECRETARY OF THE BOARD

  20. HKEXnews

    Notification Letter to Non-registered Holders of H Shares and Request Form - Arrangement of Electronic Dissemination of Corporate Communications

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:3378 on TradingView.

Listing details

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 3378, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Hanx Biopharmaceuticals (Wuhan) Co. Ltd.
Ticker
3378
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
CNE100007C34
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.